Expression of HMGB1 and its Clinical Significance in T-cell Lymphoma
Expression of HMGB1 and its Clinical Significance in T-cell Lymphoma
复制标题
DOI：
10.7314/apjcp.2012.13.11.5569
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Wang, Hui-Ling
中科院分区：
文献类型：
--
作者：
Mao, Xing-Jiang;Wang, Geng-Fu;Wang, Hui-Ling
目的：评价T细胞淋巴瘤中HMGB1表达的临床意义。方法：用抗人HMGB1和survivin抗体对120例T细胞淋巴瘤和40例反应性淋巴组织增生标本进行HMGB1和survivin免疫组织化学染色。结果：T细胞淋巴瘤组织中HMGB1和survivin的表达显着高于反应性淋巴样增生组织。 HMGB1 和 survivin 阳性表达率分别为 63.7%（65/102）和 61.8%（63/102）的 T 细胞淋巴瘤病例。虽然与性别、年龄和肿瘤位置相关，但也观察到与恶性肿瘤和临床分期的显着相关性。 Spearman等级相关分析显示，HMGB1与survivin在T细胞淋巴瘤中的表达呈正相关（P
Objectives: To evaluate the clinical significance of HMGB1 expression in T-cell lymphoma. Methods: Immunohistochemical staining for HMGB1 and survivin was performed with specimens from 120 cases of T-cell lymphoma and 40 cases of reactive lymphoid hyperplasia with antibodies against human HMGB1 and survivin. Results: The expression of HMGB1 and survivin was significantly higher in tissues of T-cell lymphoma than in reactive lymphoid hyperplasia. Positive expression of HMGB1 and survivin was observed in 63.7% (65/102) and 61.8% (63/102) of T-cell lymphoma cases, respectively. While was associated with gender, age, and tumor location, significant correlations with malignancy and clinical stage were observed. Spearman rank correlation analysis revealed that the expression of HMGB1 and survivin was positively correlated in T-cell lymphomas (P